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introduction
Mitochondrial disorders have emerged as a common cause 
of inherited metabolic diseases. The underlying biochemi-
cal defect affects the respiratory chain, which is encoded by 
genes within mitochondrial DNA (mtDNA) and the nuclear 
genome. Additional nuclear-encoded mitochondrial proteins 
are involved in mitochondrial biogenesis, the assembly of the 
respiratory chain, and the maintenance of mtDNA. As a result, 
mutations in both nuclear DNA and mtDNA can cause mito-
chondrial diseases.
Mitochondrial disorders characteristically cause an over-
lapping spectrum of disease. With a few notable exceptions, 
it is very difficult to predict the genetic defect responsible in a 
particular individual. Having excluded a handful of common 
mutations, the molecular diagnostic approach is guided by the 
muscle histochemistry or biochemistry in an affected tissue.1 
This usually involves a series of investigations aimed at exclud-
ing large-scale deletions and depletion of mtDNA, followed 
by targeted resequencing of the mitochondrial and nuclear 
genomes.2 Even with recent diagnostic advances, this can be 
time consuming and expensive, and only yields a molecu-
lar diagnosis in approximately two out of three patients.3 The 
expanding clinical spectrum means that mitochondrial disor-
ders enter the differential diagnosis of an increasing number 
of patients. There is therefore a clear need to develop a more 
streamlined and high-yield molecular approach.
Given its small size at ~16.5 kb, the majority of laboratories 
use a conventional Sanger sequencing of between 20 and 40 
overlapping polymerase chain reaction (PCR) fragments from 
each patient. Although potentially less laborious, the targeted 
microarrays4 remain expensive, often require extensive cross-
validation with Sanger sequencing, and have limited capacity 
to detect novel insertion–deletion mutations. Bespoke next- 
generation sequencing panels provide an alternative,5–11 but 
given the growing number of nuclear genes implicated in mito-
chondrial diseases, comprehensive investigation ultimately 
leads to whole-exome or -genome sequencing. It is therefore 
of great interest that mtDNA sequences have been resolved 
through off-capture sequencing using conventional whole-
exome sequence (WES) methods.12–14 Although there have been 
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Purpose: Mitochondrial disorders are a common cause of inherited 
metabolic disease and can be due to mutations affecting mitochon-
drial DNA or nuclear DNA. The current diagnostic approach involves 
the targeted resequencing of mitochondrial DNA and candidate 
nuclear genes, usually proceeds step by step, and is time consuming 
and costly. Recent evidence suggests that variations in mitochondrial 
DNA sequence can be obtained from whole-exome sequence data, 
raising the possibility of a comprehensive single diagnostic test to 
detect pathogenic point mutations.
Methods: We compared the mitochondrial DNA sequence derived 
from off-target exome reads with conventional mitochondrial DNA 
Sanger sequencing in 46 subjects.
results: Mitochondrial DNA sequences can be reliably obtained 
using three different whole-exome sequence capture kits. Coverage 
correlates with the relative amount of mitochondrial DNA in the 
original genomic DNA sample, heteroplasmy levels can be deter-
mined using variant and total read depths, and—providing there is 
a minimum read depth of 20-fold—rare sequencing errors occur at 
a rate similar to that observed with conventional Sanger sequencing.
conclusion: This offers the prospect of using whole-exome sequence 
in a diagnostic setting to screen not only all protein coding nuclear 
genes but also all mitochondrial DNA genes for pathogenic muta-
tions. Off-target mitochondrial DNA reads can also be used to assess 
quality control and maternal ancestry, inform on ethnic origin, and 
allow genetic disease association studies not previously anticipated 
with existing whole-exome data sets.
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some notable successes,15 the reliability of this approach has not 
been evaluated, particularly in determining mtDNA hetero-
plasmy. Here we compare diagnostic Sanger sequencing and 
three “off-the-shelf ” exome capture kits. We show that, provid-
ing there is a basic minimum base coverage, whole-exome cap-
ture will reliably detect mtDNA sequence variations with a low 
error rate similar to that of conventional Sanger sequencing, as 
well as detecting mtDNA heteroplasmies.
MAteriALs And MetHods
We studied 46 patients with suspected mitochondrial disease. 
All patients underwent a diagnostic workup for mtDNA dis-
ease, including long-range PCR to detect mtDNA deletions, 
and Sanger mtDNA sequencing. Having excluded a pathogenic 
mtDNA mutation, we subjected the samples to WES to investi-
gate a suspected Mendelian mitochondrial disorder, using the 
same genomic DNA sample. No insertion–deletion mutations 
were detected by Sanger sequencing, so we restricted our analy-
sis of off-target WES reads to single-nucleotide variants (SNVs).
Wes and bioinformatic pipeline
The majority, 25 of 46, of patient DNA samples used for WES were 
extracted from whole blood, 8 were from muscle, and 13 were 
from skin fibroblasts. All DNA samples were extracted using the 
same standard procedure. Paired-end WES was performed using 
three different capture kits: SureSelect Human All Exon 50Mb Kit 
(Agilent, Berkshire, UK), TruSeq Exome Enrichment Kit 62Mb 
(Illumina, San Diego, CA), or SeqCap EZ Exome Library v2.0 
(Roche Nimblegen, Madison, WI). See Supplementary Table S1 
online for sample-specific details. Sequences were aligned to the 
human reference sequence (UCSC hg19) (http://genome.ucsc.
edu/) using either BWA v0.6.2 (ref. 16) or NovoAlign v2.07.13 
(http://www.novocraft.com), were formatted using Samtools 
v0.1.18 (ref. 17), and the duplicate reads were removed using 
Picard v1.75 (http://picard.sourceforge.net/). SNVs were called 
using Varscan v2.2.2 (ref. 18) with a minimum total coverage of 5 
reads and a minimum variant read depth of 3. The mitochondrial 
variants were annotated using Annovar v.21-Feb-2013 (ref. 19) 
and its mtDNA-specific database files (hg19_MT_GRCh37). 
Minor allele frequencies of variants were obtained from an in-
house group of 269 exomes and also from 15,487 full-length 
mitochondrial sequences in NCBI-GenBank (downloaded June 
2012), which were aligned using BWA-SW20 and variants called 
using Varscan v2.2.2 (ref. 18). Custom Perl scripts were used to 
convert the hg19 mtDNA variant positions and alleles to cor-
respond to those of the revised Cambridge reference sequence 
(GenBank: NC_012920.1),21 to calculate sequence read cover-
age depth and to combine the minor allele frequencies with the 
annotated variants. mtDNA haplogroups were generated using 
Haplogrep22,23 (http://haplogrep.uibk.ac.at/) and previously 
described methods.24
real-time Pcr
Real-time PCR was performed on the original DNA samples 
used for WES to quantify mtDNA copy number. Assessment of 
mtDNA copy number was carried out using a relative, real-time 
PCR assay using a Bio-Rad iQ5 Optical System (Hercules, CA) 
as described previously.25
Mitochondrial genome sequencing
Sanger sequencing of the entire mtDNA genome was per-
formed as described previously.26 Amplicons were sequenced 
using the BigDye v3.1 kit and capillary electrophoresed on an 
ABI3130xl Genetic Analyzer (Life Technologies, Warrington, 
UK). Alignment and variant calling were performed using 
SeqScape software (v2.1.1; Applied Biosystems, Paisley, UK), 
comparing with the GenBank reference sequence for human 
mtDNA (NC_012920.1).
Assessment of mutation load by quantitative 
pyrosequencing
The mtDNA mutation load for specific alleles was assessed 
using quantitative pyrosequencing. The Pyromark Assay 
Design Software v2.0 (Qiagen, Crawley, West Sussex, UK) was 
used to design locus-specific PCR and pyrosequencing prim-
ers (Supplementary Table S2 online) for each variant, and 
pyrosequencing was performed on the Pyromark Q24 plat-
form according to the manufacturer’s protocol. Quantification 
of the heteroplasmy level of each variant was achieved using 
Pyromark Q24 software to directly compare the relevant peak 
heights of the wild-type and the mutant nucleotides at the rel-
evant position, as described previously.27
statistical analysis
The correlation plot, Pearson’s correlation coefficients, Poisson 
test statistics, and binomial exact 95% confidence intervals 
(CIs) were generated using the R statistical package (v2.15.1) 
(http://CRAN.R-project.org/doc/FAQ/R-FAQ.html).
resuLts
detecting mtdnA single-nucleotide variation in off-target 
Wes reads
An in-house WES analysis pipeline28–34 was used to detect 
SNVs in the mtDNA in genomic DNA samples from 46 
patients. Exome sequences were generated using three differ-
ent capture target kits (SureSelect Human All Exon 50Mb Kit 
(Agilent), TruSeq Exome Enrichment Kit 62Mb (Illumina), or 
SeqCap EZ Exome Library v2.0 (Nimblegen)) according to the 
manufacturers’ protocols. Sequence reads were aligned to the 
human genome reference sequence (UCSC hg19) using either 
NovoAlign (http://www.novocraft.com) or BWA v0.6.2 (ref. 16) 
(see Supplementary Table S1 online for details). The mean per-
mtDNA-base read depth from the WES was 130.5-fold (mini-
mum 2.5 and maximum 4,100.3), with just under two-thirds 
of the 46 samples exceeding a mean per-base coverage depth 
of 10-fold, and having greater than 90% of the mitochondrial 
genome covered to the minimum depth of 5-fold we required 
for variant calling (Supplementary Figure S1 online). This large 
overall mean depth was due to three patients (P12, P13, and P32) 
with exceptionally high coverage (Supplementary  Table  S1 
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online), the exclusion of which resulted in a more typical mean 
read depth of 25.7-fold (minimum 2.5 and maximum 206.6) 
for the remaining 43 patients. As shown before, the mtDNA 
sequences generated by the different capture target kits showed 
distinct patterns of per-base coverage depth,14 whereas sequences 
from the same capture targets largely followed the same cover-
age pattern but at varying read depths (Figure 1). A total of 402 
different SNVs were detected by WES; 301 SNVs were intra-
genic, of which 245 were within coding genes; 63 variants were 
nonsynonymous; and 1 variant was stop-loss (Supplementary 
Table S3 online). Eleven of the mtDNA variants were rare, with 
minor allele frequencies of less than 0.0001, and for which the 
minor allele frequencies were obtained from 15,487 full-length 
mtDNA sequences in GenBank and mtDNA variants from 269 
in-house exome sequences.
off-target read depth correlates with the relative amount 
of mtdnA
Eight of the patients’ exomes were generated from muscle DNA; 
seven of these exomes were generated using Illumina Truseq 
62Mb capture targets and had greater than 99% of the mito-
chondrial genome covered to at least 5-fold, with mean per-base 
depths ranging from 28-fold to 4,100-fold (mean = 734-fold, 
n = 7). The eighth “muscle” exome was the only one from this 
group generated using Agilent 50Mb capture targets and had 
a mean per-mtDNA base depth of 2.5-fold with only 13.2% of 
bases covered to at least 5-fold. The coverage from the “muscle” 
group was higher than for exomes derived from both blood 
and fibroblast DNA, for which the mean coverage of mtDNA 
showed a range from 3-fold to 207-fold (blood exome mean = 
22-fold, n = 25; fibroblast exome mean = 24-fold, n = 13). These 
findings were in keeping with previous observations,14 suggest-
ing that off-target read depth is related to the relative number of 
mtDNA molecules in a given tissue sample.
Real-time PCR was used to determine the mtDNA copy num-
ber for the 46 patients (data shown in Supplementary Table S1 
online). Figure 2 shows the correlation between mtDNA 
copy number from quantitative PCR and mean mtDNA base 
read depth from WES; correlations for subgroups of tissue 
type,  capture target, and WES data batch are also shown. The 
Pearson’s correlation coefficient (R2) for 40 of the patients was 
0.142 (n = 40, P = 0.382), in which 6 six patients were excluded 
from the analysis because their large values for mean cover-
age (>100-fold) and quantitative PCR (>500) were obscuring 
the results for the remaining samples. Restricting the analysis 
to the tissue subgroups increased the correlations, although 
they were not statistically significant (muscle: R2 = 0.698, n = 
8, P = 0.054; blood: R2 = 0.185, n = 25, P = 0.387; fibroblast: 
R2 = 0.208, n = 13, P = 0.496). Significant correlations were found 
by further restricting the analysis to patients sequenced using 
the Illumina Truseq 62Mb capture targets and WES aligned 
with either BWA or NovoAlign (muscle/62Mb/NovoAlign: 
R2 = 0.9913, n = 5, P = 9.8 × 10−4; blood/62Mb/BWA: R2 = 
0.880, n = 13, P = 7.5 × 10−5; fibroblast/62Mb/BWA: R2 = 0.951, 
n = 5, P = 0.013). However, nonsignificant correlations 
were found for the blood/fibroblast, Illumina Truseq 62Mb, 
Figure 1 Average mitochondrial dnA (mtdnA) base read depth of 36 illumina truseq exomes and mtdnA base read depth for individual patient 
samples sequenced using three different whole-exome capture target kits.
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and NovoAlign subgroups (blood/62Mb/NovoAlign: R2 = 0.160, 
n = 6, P = 0.762; fibroblast/62Mb/NovoAlign: R2 = 0.402, n = 7, 
P = 0.372). Similar correlations were obtained when the quan-
titative PCR data were compared directly with WES coverage 
in the region of the quantitative PCR amplicons. These obser-
vations confirm that, in general, off-target read depth appears 
to correlate with the relative amount of mtDNA, providing the 
DNA was extracted from the same tissue type and WES was 
generated by the same protocol and analysis pipeline.
Validation of Wes off-target mtdnA variants by the 
codetection of expected haplogroup markers
The haplogroups for each patient were predicted using all the 
SNV calls generated from WES for the 46 patients by using 
Figure 2 correlation between mean mitochondrial dnA (mtdnA) per base depth from whole-exome sequence and mtdnA copy number from 
quantitative polymerase chain reaction (qPcr). qPCR measurements were performed in triplicate.
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the Haplogrep software.22,23 The haplogroup predictions were 
all assigned quality scores of greater than 85%, with the excep-
tion of patient P1, who was predicted to belong to haplogroup 
R6a but with a lower-quality score of 73%. Patient haplogroup 
distribution (Supplementary Table S4 online) was not sig-
nificantly different from that of UK controls,24 suggesting that 
the SNV calls from WES appear to be genuine sequence vari-
ants and can be used to determine a patient’s mitochondrial 
haplogroup. This may be of value in forensic and population 
genetic studies or as part of the quality-control procedure when 
analyzing WES data.
coverage threshold for the detection of Wes off-target 
mtdnA variants
SNVs called by the analysis pipeline were compared with vari-
ants identified using diagnostic Sanger sequencing protocols. 
Supplementary Table S5 online shows the number of SNVs 
detected in each patient for each sequencing technique rela-
tive to the revised Cambridge reference sequence (GenBank: 
NC_012920.1). A total of 762,174 bases of mtDNA were 
sequenced across the 46 patients. Sanger sequence detected 
SNVs at 1,277 bases, and WES detected SNVs at 1,110 bases; 
1,079 SNVs were codetected by the two sequencing technolo-
gies. The vast majority of SNVs (185/198) that were detected 
only by Sanger sequencing corresponded to bases for which the 
WES read depth was less than the fivefold threshold for SNV 
calling. In total, 106,700 of 762,174 (14%) bases failed to meet 
the fivefold calling threshold, resulting in SNVs being missed 
by WES in 19 patients; only 6 patients had all 16,569 base pairs 
of their mtDNA completely “covered” (fivefold) by WES. This 
led us to propose a minimum mean per-mtDNA-base coverage 
threshold of 20-fold in WES to ensure that the vast majority 
of mtDNA SNVs are detected. In our data, 20 of 46 patients 
reached this threshold, with 330,684 of 331,380 (99.8%) bases 
sequenced to the minimum fivefold by WES and 0 of 512 SNVs 
missed due to low coverage.
Tables 1 and 2 show 13 mtDNA SNVs were detected only by 
the original Sanger sequence, despite adequate WES read depth 
at each base (greater than fivefold), and 14 mtDNA SNVs were 
detected only by WES. Replicate Sanger sequencing was then 
performed from the original patient DNA across each one of 
these 27 variant sites. Furthermore, 10 of 13 SNVs originally 
detected by Sanger sequencing were not detected in the repeat 
Sanger sequence and were therefore likely to be sequencing 
artifacts from the initial Sanger sequencing. Of the remaining 
three SNVs, two (m.240A>G and m.16186C>T) could be seen 
in WES by manually evaluating the reads that showed potential 
heteroplasmy, but they had low variant base quality scores.
Pyrosequencing from the original DNA sample identified 
these two variants as being 32 and 86% heteroplasmic as com-
pared to heteroplasmy predictions from WES reads of 18% 
(95% CI: 4–43%, CIs based on the binomial distribution and 
allele read frequencies) and 17% (95% CI: 6–36%), respectively. 
For m.240A>G, the 95% CI for the WES heteroplasmy estimate 
Figure 3 Binomial 95% confidence intervals for the detection of heteroplasmies at differing whole-exome sequence coverage depths. Intervals 
are shown for total read coverage depths (n) of 10-, 20-, 30-, and 50-fold, with the total range of variant allele counts (v) from 1 to n − 1, and the resulting 
estimated heteroplasmies (v/n) of between 0.0 and 1.0 (0–100%). The plots demonstrate a reduction in the size of the confidence intervals at increasing exome 
read depths, indicating that the higher the total depth, the closer the estimated heteroplasmy level is likely to be to the true heteroplasmy level.
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(4–43%) included the pyrosequencing result (32%). The total 
WES read depth at m.240A>G was 17-fold, with 3 reads con-
taining the variant allele (3 of 17 = 18%). Greater read coverage 
depth would decrease the width of these CIs and increase the 
accuracy of the WES heteroplasmy estimate, as demonstrated 
in Figure 3. On the other hand, the 95% CIs for the WES het-
eroplasmy estimate for m.16186C>T (6–36%) did not contain 
the value obtained by pyrosequencing (86%). m.16186C>T is 
located within a poly-C tract, which could have affected WES 
read alignment, thus explaining why the pyrosequencing het-
eroplasmy measurement was different from the WES estimate. 
The third Sanger-only variant (m.574A>C) was not identified 
by pyrosequencing; this variant is also located next to a poly-C 
tract, which may be interfering with the variant detection from 
both WES and pyrosequencing.
Overall, the false-positive rate for Sanger sequencing was 10 
of 762,174 total or 0.0013%, which is in keeping with previous 
estimates and corresponds to the DNA polymerase fidelity.35 
On the other hand, 7 of 14 SNVs (24 of 31 bases), which were 
only identified by WES off-target reads at >4-fold depth, were 
not seen in the repeat Sanger sequence. This corresponds to an 
error rate of 24 of 762,174 or 0.0031% for WES, which shows 
a marginally significant increase as compared to the Sanger 
rate (Poisson exact ratio test (P = 0.02431) of rate ratio = 1). 
However, considering that the false-positive calls from WES 
repeatedly occurred at the same bases located in the region of 
the poly-C sequence tract m.16184–16193, with only two WES 
false calls outside of this region, the false call rate from WES for 
the vast majority of the mitochondrial genome is actually sig-
nificantly lower than that of Sanger sequencing (2 of 761,714 or 
0.0003% (WES) vs. 10 of 761,714 or 0.0013% (Sanger); Poisson 
exact ratio test (P = 0.03857) of rate ratio = 1). Of the seven 
SNVs that were originally identified only by WES but subse-
quently confirmed by repeat Sanger sequence, five were located 
in the noncoding control region (m.250T>C, m.16093T>C, 
m.16150C>T, m.16343A>G, and m.16390G>A) and one was a 
synonymous SNV in MTND2 (m.5009A>G), and so these were 
assumed to be of no functional consequence. The seventh SNV, 
which was located in MTRNR2 (m.2905A>G) and appeared 
from the WES, reads to be 42% heteroplasmic (95% CI: 26–
69%). Pyrosequencing estimated the MTRNR2 variant to be 
44% heteroplasmic, which fell within the confidence interval 
from the WES data.
the detection of mtdnA heteroplasmy by off-target Wes
Next we looked for evidence of heteroplasmic SNVs in 13 of the 
46 patients who had a mean mtDNA read depth greater than 
30-fold, focusing on heteroplasmy levels between 10 and 90%. 
All 13 of the patients had SNVs that appeared to be hetero-
plasmic, but all were at the same nine base positions and were 
therefore assumed to be false calls (Supplementary Table S6 
online). Three of the patients had SNVs that appeared to show 
heteroplasmy unique to the individual person (Supplementary 
Table S7 online). Heteroplasmic variants were confirmed by 
pyrosequencing for three out of five of these variants, at levels 
that were within the 95% CIs for the estimates from WES reads. 
The other two variants were detected but were homoplasmic on 
the pyrosequencing. These false heteroplasmy predictions from 
the WES reads were assumed to have occurred due to errone-
ous “background” variant base calls of threefold and fivefold, 
as compared to most base positions, which had only a “back-
ground” variant call level of between zerofold and twofold.
discussion
Here we show that off-target WES reads can be used to reliably 
determine the mtDNA sequence, providing there is adequate 
read depth. With >20-fold mean coverage, the error rate is only 
marginally higher than that of conventional diagnostic Sanger 
sequencing, and if the WES errors that repeatedly occur at the 
poly-C sequence tract are taken into account, the error rate is 
marginally lower in WES as compared to Sanger sequencing. 
Given the potential role of mtDNA mutations in a broad range 
of human disease phenotypes, we suggest that mtDNA analysis 
should be included in a diagnostic exome analysis pipeline.
Despite the exciting prospect of acquiring this potentially 
revealing data “gratis,” any positive results should be interpreted 
with caution. Although only one sample was sequenced after 
Nimblegen capture, limiting our ability to make a formal com-
parison across all three capture platforms, the per-mtDNA-base 
coverage plots (Figure 1) generated from our study confirm 
previous findings describing four peaks with Nimblegen tar-
gets.14 These peaks correspond to nuclear-encoded mitochon-
drial sequences, leading to false mtDNA calls and potential 
heteroplasmy. On the other hand, here we show that nuclear-
encoded mitochondrial sequences do not pose a problem for 
the accurate calling of mtDNA SNVs and detection of het-
eroplasmy when using Illumina Truseq (62 Mb) or Agilent 
SureSelect (50 Mb) targeted sequence and a standard WES 
analysis pipeline, in which there is no need for an additional 
realignment of mitochondrial sequence reads to the mitochon-
drial genome as has been previously suggested.14 However, with 
both of these platforms, we observed dips in coverage in the 
region of the origin of light-strand replication (Ori-L, Figure 
1). Consistency between different capture technologies suggests 
that the reduced coverage reflects the local sequence context, 
making these regions vulnerable to sequencing error when 
the mean coverage is low. Furthermore, common pathogenic 
mtDNA mutations are found in approximately 1 out of 300 of 
the general population, so any sequencing result must be inter-
preted in the correct clinical context. It is also worth noting that 
rare, region-specific polymorphic variants may not be listed on 
public databases. Having a population-matched control data-
base has proven invaluable in our experience, allowing the early 
identification and exclusion of likely polymorphisms.
Finally, although this study was not specifically designed 
to determine the threshold for detecting heteroplasmy, it was 
found that mtDNA heteroplasmies could be detected in our 
data at levels of between approximately 40 and 90% from WES 
when the sequence had a mean read coverage depth >30-fold. 
It remains to be seen whether WES data can be used to reliably 
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detect lower levels of heteroplasmy, which is more likely to 
be possible at greater coverage depths, as shown in Figure 3. 
However, tissue-specific pathogenic mtDNA point mutations 
are a rare but well-recognized cause of mitochondrial disease, 
so the absence of a pathogenic mtDNA mutation in WES from 
blood DNA does not exclude the possibility of a pathogenic 
mtDNA point mutation in skeletal muscle. Given our finding 
that the WES of skeletal muscle DNA yields excellent mtDNA 
coverage, there is a strong argument in favor of WES of DNA 
extracted from a clinically affected tissue for comprehensive 
genetic analysis of mtDNA and relevant nuclear genes in a 
patient with suspected mitochondrial disease.
The reliable extraction of mtDNA sequence from WES data 
has several advantages. Geographically restricted mtDNA 
sequence motifs enable an evaluation of maternal ancestry and 
can thus be incorporated into quality-control algorithms when 
analyzing the nuclear DNA sequence. MtDNA genotyping may 
be of value for forensic or population genetic studies. Common 
mtDNA variants have been associated with several common 
diseases, and the acquired mtDNA sequence can be incorpo-
rated into the analysis of complex traits. Finally, given the broad 
clinical phenotype, mtDNA disorders enter the differential 
diagnosis of a wide range of diseases. Our analysis shows that 
WES data, aimed at the diagnosis of suspected nuclear genetic 
disorders, can also be used to diagnose pathogenic mtDNA 
mutations, providing the level of heteroplasmy is above the 
detection threshold. As a first-line test, currently WES would be 
a costly way of investigating a suspected mitochondrial disor-
der presenting with the classic phenotype of a specific mtDNA 
disease. However, as costs fall and the analysis becomes more 
automated, WES may become the first port of call for clinicians 
suspecting mitochondrial disease in the future.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
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